InSilico Medicine Fully Exercises Over-Allotment Option, Boosting Share Capital After Strong IPO Demand
I'm PortAI, I can summarize articles.
InSilico Medicine Cayman TopCo has fully exercised its over-allotment option from its recent IPO, issuing 14,203,500 additional shares at HK$24.05 each, which is 15% of the initial offering. This move increases the total issued share capital to 571,622,000 shares and is expected to enhance the stock's free float while slightly diluting existing holdings. The new shares are set to begin trading on January 21, 2026, and the company operates in the biotechnology sector, focusing on drug discovery and AI-driven research.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments